Overview

This course is a comprehensive review of hematologic malignancies focusing on research developments over the preceding year and their application to the patient care journey. Didactic presentations will include case discussion with Penn faculty and community experts. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application.

Learning Objectives

At the completion of this course, participants should be able to:

• Evaluate evolving treatment strategies for mantle cell lymphoma.
• Explain equal access to transplant and the use of mismatched donors.
• Describe cell therapy approaches for autoimmune diseases.
• Analyze progress in GVHD therapies.
• Evaluate emerging treatment options for AML.
• Apply current management of MDS and bone marrow failure syndromes.
• Summarize updates in CML and myeloproliferative disease.
• Analyze current and future immunotherapies for acute leukemias (including CD33 CAR T-cell therapy).
• Explain current approaches to smoldering myeloma and amyloidosis.
• Review initial therapy for multiple myeloma, including the role of transplant.
• Evaluate the role of immunotherapy in myeloma treatment.
• Analyze investigational therapies for relapsed myeloma.

Target Audience

This activity has been designed for hematologists, medical and radiation oncologists, primary care physicians, pathologists, hematology/oncology fellows, oncology nurses, oncology social workers, and other healthcare professionals involved in the treatment of patients with blood cancer.

Accreditation

Penn Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.